Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Exclusion Criteria

• •Female
• •Male vaccinated prior to the October 2009 FDA date of first licensure of GARDASIL™ for males
• •Male who received all doses of GARDASIL™ outside of the health plan
• •Male \< 9 and \> 26 years of age at first dose
• •Male not part of health plan at each dose
• •3-dose vaccination regimen given over a period \> 12 months
• •Less than 28-day interval between first and second dose
• •Less than 12 weeks between the second and third dose
• •Less than 24 weeks between first and third dose
• •\- Male with less than 12 months of health plan membership prior to first dose of GARDASIL™